Drug, alcohol and tobacco use disorders are a global burden affecting millions of people.
Despite decades of research, treatment options are sparse or missing, and relapse rates are …

Glucagon-like peptide-1 (GLP-1) is a human incretin hormone derived from the proglucagon
molecule. GLP-1 receptor agonists are frequently used to treat type 2 diabetes mellitus and …

Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in
the neurobiology of addictive behaviors, and GLP-1 analogues may be used for the …

Alcohol-related liver disease (ALD) is a major cause of liver disease and represents a global
burden, as treatment options are scarce. Whereas 90% of ethanol abusers develop …

Phasic dopamine activity is evoked by reliable predictors of food reward and plays a role in
cue-triggered, goal-directed behavior. While this important signal is modulated by …

Animal studies have related glucagon‐like peptide 1 receptor agonists (GLP‐1) to lower
alcohol intake. We examined whether GLP‐1 was associated with risk of alcohol‐related …

Growing evidence suggests that the glucagon‐like peptide‐1 (GLP‐1) system modulates
alcohol seeking and consumption, and GLP‐1 analogues may represent novel …

Growing evidence suggests that the glucagon-like peptide-1 (GLP-1) system is involved in
mechanisms underlying alcohol seeking and consumption. Accordingly, the GLP-1 receptor …

Highly palatable foods and substance of abuse have intersecting neurobiological, metabolic
and behavioral effects relevant for understanding vulnerability to conditions related to food …

The surge in popularity of semaglutide (Ozempic, Wegovy, Rybelsus) and other glucagon-
like-peptide 1 (GLP-1) receptor agonists has been accompanied by widespread reports of …